초록 ▼

The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk vaccine compositions stabilized with these stabilizers, particularly dry vaccine compositions prepared from th

The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk vaccine compositions stabilized with these stabilizers, particularly dry vaccine compositions prepared from these bulk vaccine compositions, and to methods for stabilizing one or more live attenuated flaviviruses.

대표청구항 ▼

1. A stabilizer for compositions comprising one or more live attenuated flaviviruses, which comprises, in an aqueous solution without proteins of animal origin and without added salts having divalent cations, a buffer,2.5% to 6.5% of sorbitol,2.5% to 13% of sucrose,0 to 7.5% of trehalose and/or 0 to

1. A stabilizer for compositions comprising one or more live attenuated flaviviruses, which comprises, in an aqueous solution without proteins of animal origin and without added salts having divalent cations, a buffer,2.5% to 6.5% of sorbitol,2.5% to 13% of sucrose,0 to 7.5% of trehalose and/or 0 to 7.5% of a disaccharide other than sucrose or trehalose or a trisaccharide,0.2% to 0.5% of urea,0.8% to 2.5% of an amino acid mixture comprising arginine (Arg), cystine (Cys-Cys), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (Val), alanine (Ala), asparagine (Asn), aspartic acid (Asp), glutamic acid (Glu), glycine (Gly), proline (Pro) and serine (Ser). 2. The stabilizer as claimed in claim 1, which comprises one or more buffers selected from the group consisting of TRIS (tris(hydroxymethyl)-aminomethane), HEPES (2-(4-(2-hydroxyethyl)-1-piperazinyl)ethane-sulfonic acid) and potassium phosphate and/or sodium phosphate. 3. The stabilizer as claimed in claim 2, wherein the TRIS is present at a concentration of from 5 to 10 mM. 4. The stabilizer as claimed in claim 2, wherein the HEPES is present at a concentration of from 7.5 to 20 mM. 5. The stabilizer as claimed in claim 1, comprising 3.8% (w/v) of sorbitol,7.5% (w/v) of sucrose,5.5% (w/v) of trehalose,0.25% (w/v) of urea and1.5% (w/v) of the amino acid mixture. 6. A stabilized bulk aqueous vaccine composition comprising one or more live attenuated flaviviruses and the stabilizer as claimed in claim 1. 7. The vaccine composition as claimed in claim 6, which comprises one or more live attenuated dengue (DEN) virus serotypes. 8. The vaccine composition as claimed in claim 6, which comprises live attenuated yellow fever (YF) viruses. 9. The vaccine composition as claimed in claim 6, which comprises live attenuated West Nile (WN) virus disease viruses. 10. The vaccine composition as claimed in claim 6, which comprises live attenuated Japanese encephalitis (JE) viruses. 11. The vaccine composition as claimed in claim 6, which comprises one or more chimeric live attenuated flaviviruses. 12. The vaccine composition as claimed in claim 11, which comprises one or more serotypes of a chimeric YF-DEN (yellow fever-dengue) virus. 13. The vaccine composition as claimed in claim 11, which comprises a chimeric YF-WN (yellow fever-West Nile virus) virus. 14. The vaccine composition as claimed in claim 11, which comprises a chimeric YF-JE (yellow fever-Japanese encephalitis) virus. 15. A method for stabilizing one or more live attenuated flaviviruses, comprising diluting a purified and concentrated viral harvest comprising one or more live attenuated flaviviruses by adding stabilizer so as to obtain the final concentrations of the stabilizer defined according to claim 1 in order to obtain a stabilized bulk aqueous vaccine composition comprising said one or more live attenuated flaviviruses. 16. The stabilization method as claimed in claim 15, comprising drying the aqueous composition by means of a method selected from the group of foam-drying, spray-drying or freeze-foam-drying. 17. The stabilization method as claimed in claim 15, comprising drying the aqueous composition by means of freeze-drying method. 18. The stabilization method as claimed in claim 15, comprising drying the aqueous composition by means of spray-freeze-drying method. 19. The stabilization method as claimed in claim 17, wherein, in a first step, the aqueous solution is frozen in the form of uniform particles or of beads, and wherein, in a second step, the frozen uniform particles or beads are subjected to drying in order to obtain a stabilized dry product in the form of uniform particles or of beads. 20. The stabilization method as claimed in claim 19, wherein the uniform particles or beads of the stabilized dry product have a diameter of approximately 100 μm to 1500 μm. 21. The stabilization method as claimed in claim 20, wherein the uniform particles or beads of the stabilized dry product have a diameter of approximately 500 μm to 1000 μm. 22. A dry vaccine composition obtained by drying the stabilized bulk composition as claimed in claim 6. 23. The dry vaccine composition as claimed in claim 22, which is present in the form of uniform particles or of beads. 24. The dry vaccine composition as claimed in claim 23, wherein each particle or each bead contains a mixture of various live attenuated and/or chimeric live attenuated flaviviruses. 25. The dry vaccine composition as claimed in claim 23, wherein each particle or each bead contains live attenuated and/or chimeric live attenuated flaviviruses of a single type. 26. A method for preparing a vaccine, comprising the step of reconstituting the composition as claimed in claim 22 with an aqueous solution. 27. A flaviviral vaccine kit comprising a first container containing the dry vaccine composition as claimed in claim 22 and a second container containing an aqueous solution for reconstituting the vaccine. 28. The kit as claimed in claim 27, wherein each particle or bead of the dry vaccine composition in the first container contains a mixture of various live attenuated and/or chimeric live attenuated flaviviruses.